Notch signaling: an emerging therapeutic target for cancer treatment.

The Notch pathway is involved in cell proliferation, differentiation and survival. The Notch signaling pathway is one of the most commonly activated signaling pathways in cancer. Alterations include activating mutations and amplification of the Notch pathway, which play key roles in the progression of cancer. Accumulating evidence suggests that the pharmacological inhibition of this pathway can overcome chemoresistance. Efforts have been taken to develop Notch inhibitors as a single agent or in combination with clinically used chemotherapeutics to treat cancer. Some Notch inhibitors have been demonstrated to have therapeutic efficacy in preclinical studies. This review summarizes the recent studies and clinical evaluations of the Notch inhibitors in cancer.

[1]  A. Maitra,et al.  A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma , 2014, Investigational New Drugs.

[2]  M. Gessler,et al.  Mechanisms of epigenetic and cell-type specific regulation of Hey target genes in ES cells and cardiomyocytes. , 2015, Journal of molecular and cellular cardiology.

[3]  P. Wei,et al.  Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design , 2010, Molecular Cancer Therapeutics.

[4]  A. Egloff,et al.  Molecular Pathways: Context-Dependent Approaches to Notch Targeting as Cancer Therapy , 2012, Clinical Cancer Research.

[5]  Sun-Ok Yoon,et al.  GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation , 2014, Cell cycle.

[6]  A. Maitra,et al.  Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. , 2013, Cancer letters.

[7]  J. Taub,et al.  New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. , 2014, Cellular signalling.

[8]  Pamela A. Hoodless,et al.  Slug is a direct Notch target required for initiation of cardiac cushion cellularization , 2008, The Journal of cell biology.

[9]  H. Maehr,et al.  HES1-mediated inhibition of Notch1 signaling by a Gemini vitamin D analog leads to decreased CD44+/CD24−/low tumor-initiating subpopulation in basal-like breast cancer , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[10]  L. Audoly,et al.  Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies , 2010, Biologics : targets & therapy.

[11]  G. Berx,et al.  Regulatory networks defining EMT during cancer initiation and progression , 2013, Nature Reviews Cancer.

[12]  D. Brazil,et al.  Jagged/Notch signalling is required for a subset of TGFβ1 responses in human kidney epithelial cells. , 2010, Biochimica et biophysica acta.

[13]  A. Capobianco,et al.  Notch signalling in solid tumours: a little bit of everything but not all the time , 2011, Nature Reviews Cancer.

[14]  A. Capobianco,et al.  Notch signaling drives stemness and tumorigenicity of esophageal adenocarcinoma. , 2014, Cancer research.

[15]  D. Carbone,et al.  EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling. , 2014, Cancer research.

[16]  Jino Park,et al.  Notch1 is required for hypoxia-induced proliferation, invasion and chemoresistance of T-cell acute lymphoblastic leukemia cells , 2013, Journal of Hematology & Oncology.

[17]  L. Bolondi,et al.  Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3β phosphorylation and p21 down-regulation in hepatocellular carcinoma , 2013, Oncotarget.

[18]  T. Yeatman,et al.  A phase II study of RO4929097 in metastatic colorectal cancer. , 2012, European journal of cancer.

[19]  T. Dønnem,et al.  Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer , 2010, Cancer.

[20]  L. Mao.  NOTCH Mutations: Multiple Faces in Human Malignancies , 2015, Cancer Prevention Research.

[21]  J. Olson,et al.  Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Eberhart,et al.  Prolonged Inhibition of Glioblastoma Xenograft Initiation and Clonogenic Growth following In Vivo Notch Blockade , 2013, Clinical Cancer Research.

[23]  Diane D. Liu,et al.  A High Notch Pathway Activation Predicts Response to γ Secretase Inhibitors in Proneural Subtype of Glioma Tumor‐Initiating Cells , 2014, Stem cells.

[24]  Steven J. M. Jones,et al.  A Notch‐dependent transcriptional hierarchy promotes mesenchymal transdifferentiation in the cardiac cushion , 2014, Developmental dynamics : an official publication of the American Association of Anatomists.

[25]  Xianzhi Lin,et al.  Latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus promotes angiogenesis through targeting notch signaling effector Hey1. , 2014, Cancer research.

[26]  Thijs J. Hagenbeek,et al.  Therapeutic antibody targeting of individual Notch receptors , 2010, Nature.

[27]  J. Minna,et al.  Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. , 2000, Journal of the National Cancer Institute.

[28]  K. Capaccione,et al.  The Notch signaling pathway as a mediator of tumor survival. , 2013, Carcinogenesis.

[29]  Robert Beckman,et al.  Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Tan,et al.  Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model , 2013, British Journal of Cancer.

[31]  A. Oza,et al.  A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) , 2012, British Journal of Cancer.

[32]  N. Giese,et al.  Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression. , 2014, Carcinogenesis.

[33]  S. Keir,et al.  Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling , 2012, Pediatric blood & cancer.

[34]  I. Screpanti,et al.  γ‐Secretase inhibitor I induces apoptosis in chronic lymphocytic leukemia cells by proteasome inhibition, endoplasmic reticulum stress increase and notch down‐regulation , 2013, International journal of cancer.

[35]  L. Espinosa,et al.  Bmi1 regulates murine intestinal stem cell proliferation and self-renewal downstream of Notch , 2015, Development.

[36]  S. Duchi,et al.  Pharmacologic inhibition of vacuolar H+ ATPase reduces physiologic and oncogenic Notch signaling , 2013, Molecular oncology.

[37]  Manuel Serrano,et al.  Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. , 2012, Cancer cell.

[38]  L. Poliseno,et al.  The Novel Gamma Secretase Inhibitor RO4929097 Reduces the Tumor Initiating Potential of Melanoma , 2011, PloS one.

[39]  S. Barry,et al.  MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo , 2012, Molecular Cancer Therapeutics.

[40]  U. Lendahl,et al.  Frequency and distribution of Notch mutations in tumor cell lines , 2015, BMC Cancer.

[41]  P. Rejto,et al.  PEST Domain Mutations in Notch Receptors Comprise an Oncogenic Driver Segment in Triple-Negative Breast Cancer Sensitive to a γ-Secretase Inhibitor , 2015, Clinical Cancer Research.

[42]  G. Zheng,et al.  Notch1-induced T cell leukemia can be potentiated by microenvironmental cues in the spleen , 2014, Journal of Hematology & Oncology.

[43]  K. Jones,et al.  Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. , 2011, Cancer research.

[44]  Massimo Cristofanilli,et al.  Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells , 2012, Breast Cancer Research and Treatment.

[45]  P. Rejto,et al.  Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models , 2012, Clinical Cancer Research.

[46]  E. Campo,et al.  The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells , 2014, Leukemia.

[47]  Shiying Yu,et al.  Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis , 2015, PloS one.

[48]  S. Ansell,et al.  MRK003, a γ-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma , 2012, Leukemia.

[49]  T. Waldmann,et al.  Augmented efficacy with the combination of blockade of the NOTCH-1 pathway, Bortezomib and Romidepsin in a murine MT-1 adult T cell leukemia model , 2014, Leukemia.

[50]  Jingru Zhang,et al.  Curcumin inhibits proliferation and invasion of osteosarcoma cells through inactivation of Notch‐1 signaling , 2012, The FEBS journal.

[51]  Zachary C. Dobbin,et al.  Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer , 2014, Oncotarget.

[52]  Ava C. Carter,et al.  Notch inhibition allows oncogene independent generation of iPS cells , 2014, Nature chemical biology.

[53]  M. Huang,et al.  Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. , 2013, Cancer research.

[54]  D. Tuveson,et al.  Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma , 2012, The Journal of experimental medicine.

[55]  A. Llombart‐Bosch,et al.  Suppression of deacetylase SIRT1 mediates tumor-suppressive NOTCH response and offers a novel treatment option in metastatic Ewing sarcoma. , 2014, Cancer research.

[56]  Mukund Seshadri,et al.  Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts , 2014, PloS one.

[57]  G. Pelosi,et al.  Alterations of the Notch pathway in lung cancer , 2009, Proceedings of the National Academy of Sciences.

[58]  P. LoRusso,et al.  Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097 , 2012, Clinical Cancer Research.

[59]  T. Dang,et al.  γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer , 2012, British Journal of Cancer.

[60]  James X. Song,et al.  Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  Percy,et al.  A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) , 2013, Investigational New Drugs.

[62]  A. Minn,et al.  Triple negative breast cancer initiating cell subsets differ in functional and molecular characteristics and in γ-secretase inhibitor drug responses , 2013, EMBO molecular medicine.

[63]  Sherry X. Yang,et al.  Targeting notch signaling pathway in cancer: clinical development advances and challenges. , 2014, Pharmacology & therapeutics.

[64]  J. Kolesar,et al.  A multicenter phase 1 study of γ -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors , 2015, Investigational New Drugs.

[65]  Hua Wu,et al.  Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis , 2015, Scientific Reports.

[66]  A. Jimeno,et al.  A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014 , 2014, Clinical Cancer Research.

[67]  Frank McCormick,et al.  Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.

[68]  Hua Wu,et al.  Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application , 2014, Journal of Hematology & Oncology.

[69]  I. Ellis,et al.  Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells , 2014, Breast Cancer Research and Treatment.

[70]  Jun Yao,et al.  Combination treatment of PD98059 and DAPT in gastric cancer through induction of apoptosis and downregulation of WNT/β-catenin , 2013, Cancer biology & therapy.

[71]  M. Wicha,et al.  Notch Reporter Activity in Breast Cancer Cell Lines Identifies a Subset of Cells with Stem Cell Activity , 2015, Molecular Cancer Therapeutics.

[72]  K. Albain,et al.  Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence , 2011, British Journal of Cancer.

[73]  Y. Li,et al.  Aspartate β-hydroxylase expression promotes a malignant pancreatic cellular phenotype , 2014, Oncotarget.

[74]  P. Pantazis,et al.  Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism , 2011, Journal of nanobiotechnology.

[75]  S. Anant,et al.  Honokiol in Combination with Radiation Targets Notch Signaling to Inhibit Colon Cancer Stem Cells , 2012, Molecular Cancer Therapeutics.

[76]  Junli Guo,et al.  Inhibition of Notch Signaling by a γ-Secretase Inhibitor Attenuates Hepatic Fibrosis in Rats , 2012, PloS one.

[77]  A. Lazar,et al.  New, Tolerable γ-Secretase Inhibitor Takes Desmoid Down a Notch , 2014, Clinical Cancer Research.

[78]  Ian Krop,et al.  Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors , 2013, Clinical Cancer Research.

[79]  A. Harris,et al.  Delta-like ligand 4-notch blockade and tumor radiation response. , 2011, Journal of the National Cancer Institute.

[80]  R. Kumar,et al.  Companion Diagnostics and Cancer Biomarkers Coordinate Hyperactivation of Notch 1 and Ras / MAPK Pathways Correlates with Poor Patient Survival : Novel Therapeutic Strategy for Aggressive Breast Cancers , 2014 .

[81]  Gregory A. Wyant,et al.  Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy , 2012, Proceedings of the National Academy of Sciences.

[82]  A. Oza,et al.  A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors , 2013, Investigational New Drugs.

[83]  D. Semela,et al.  Constitutive Notch2 signaling induces hepatic tumors in mice , 2013, Hepatology.

[84]  S. Akiyama,et al.  Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity , 2012, Molecular Cancer Therapeutics.

[85]  M. Campone,et al.  γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells , 2012, Breast Cancer Research.

[86]  Emma R. Andersson,et al.  Therapeutic modulation of Notch signalling — are we there yet? , 2014, Nature Reviews Drug Discovery.

[87]  P. Du,et al.  γ-Secretase inhibitor, DAPT inhibits self-renewal and stemness maintenance of ovarian cancer stem-like cells in vitro , 2011, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[88]  V. Sondak,et al.  Phase 2 study of RO4929097, a gamma‐secretase inhibitor, in metastatic melanoma: SWOG 0933 , 2015, Cancer.

[89]  D. Gallahan,et al.  The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4) , 1997, Oncogene.